- Home
- IGMS vs IAE Comparison
IGMS vs IAE Comparison
Compare IGMS & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- IAE
- Stock Information
- Founded
- IGMS 1993
- IAE 2007
- Country
- IGMS United States
- IAE United States
- Employees
- IGMS N/A
- IAE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- IAE Trusts Except Educational Religious and Charitable
- Sector
- IGMS Health Care
- IAE Finance
- Exchange
- IGMS Nasdaq
- IAE Nasdaq
- Market Cap
- IGMS 82.1M
- IAE 68.1M
- IPO Year
- IGMS 2019
- IAE N/A
- Fundamental
- Price
- IGMS $1.38
- IAE $6.35
- Analyst Decision
- IGMS Hold
- IAE
- Analyst Count
- IGMS 8
- IAE 0
- Target Price
- IGMS $6.14
- IAE N/A
- AVG Volume (30 Days)
- IGMS 368.0K
- IAE 46.3K
- Earning Date
- IGMS 03-06-2025
- IAE 01-01-0001
- Dividend Yield
- IGMS N/A
- IAE 10.21%
- EPS Growth
- IGMS N/A
- IAE N/A
- EPS
- IGMS N/A
- IAE N/A
- Revenue
- IGMS $2,918,000.00
- IAE N/A
- Revenue This Year
- IGMS $26.85
- IAE N/A
- Revenue Next Year
- IGMS $125.17
- IAE N/A
- P/E Ratio
- IGMS N/A
- IAE N/A
- Revenue Growth
- IGMS 57.64
- IAE N/A
- 52 Week Low
- IGMS $1.26
- IAE $5.31
- 52 Week High
- IGMS $22.50
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- IAE 63.88
- Support Level
- IGMS $1.26
- IAE $6.17
- Resistance Level
- IGMS $1.54
- IAE $6.33
- Average True Range (ATR)
- IGMS 0.13
- IAE 0.09
- MACD
- IGMS 0.22
- IAE 0.02
- Stochastic Oscillator
- IGMS 29.27
- IAE 75.06
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.